Details of Drug-Drug Interaction
| Drug General Information (ID: DDIZIUC0Y5) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Methazolamide | Drug Info | Nitrous acid | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Carbonic Anhydrase Inhibitors | Antidotes | |||||||
| Structure | |||||||||
| Mechanism of Methazolamide-Nitrous acid Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Additive hypotensive effects Click to Show/Hide Mechanism Graph | |||||||||
![]() |
|||||||||
| Drug Name | Methazolamide | Nitrous acid | |||||||
| Mechanism |
Hypotensive effects Carbonic anhydrase I Inhibitor |
Hypotensive effects Guanylate cyclase Agonist |
|||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Carbonic anhydrase I |
×
Structure
Sequence
MASPDWGYDDKNGPEQWSKLYPIANGNNQSPVDIKTSETKHDTSLKPISVSYNPATAKEIINVGHSFHVNFEDNDNRSVLKGGPFSDSYRLFQFHFHWGSTNEHGSEHTVDGVKYSAELHVAHWNSAKYSSLAEAASKADGLAVIGVLMKVGEANPKLQKVLDALQAIKTKGKRAPFTNFDPSTLLPSSLDFWTYPGSLTHPPLYESVTWIICKESISVSSEQLAQFRSLLSNVEGDNAVPMQHNNRPTQPLKGRTVRASF
|
|||||||
| Gene Name | CA1 | ||||||||
| Uniprot ID | CAH1_HUMAN | ||||||||
| KEGG Pathway | hsa:759 | ||||||||
| Protein Family | Alpha-carbonic anhydrase family | ||||||||
| Protein Function |
Catalyzes the reversible hydration of carbon dioxide (PubMed:10550681, PubMed:18618712). Can hydrate cyanamide to urea (PubMed:10550681).
Click to Show/Hide
|
||||||||
| Key Mechanism Factor 2 | |||||||||
| Factor Name | Guanylate cyclase soluble | Structure Sequence | |||||||
| Protein Family | Adenylyl cyclase class-4/guanylyl cyclase family | ||||||||
| Protein Function |
There are two types of guanylate cyclases: soluble forms and membrane-associated receptor forms. Activated by nitric oxide in the presence of magnesium or manganese ions.
Click to Show/Hide
|
||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Sodium nitrite should be used with caution in the presence of concomitant antihypertensive agents, diuretics, vasodilators, or PDE5 inhibitors. Hemodynamics should be monitored during and after administration of sodium nitrite, and the infusion rate decreased if significant hypotension occurs. In addition, methemoglobin levels should be monitored and oxygen administered during treatment whenever possible. | ||||||||

